Industry
Biotechnology
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Loading...
Open
14.35
Mkt cap
1.3B
Volume
1.8M
High
14.35
P/E Ratio
-13.72
52-wk high
18.07
Low
13.30
Div yield
N/A
52-wk low
11.30
Portfolio Pulse from Benzinga Newsdesk
August 28, 2024 | 8:14 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 4:16 pm
Portfolio Pulse from Avi Kapoor
August 01, 2024 | 12:17 pm
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 11:40 am
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 10:32 am
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 10:09 am
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 9:30 am
Portfolio Pulse from Benzinga Newsdesk
July 30, 2024 | 3:38 pm
Portfolio Pulse from Benzinga Newsdesk
July 30, 2024 | 11:39 am
Portfolio Pulse from Benzinga Newsdesk
July 30, 2024 | 11:17 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.